Dr. Issa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
403 Haddon Ave
Philadelphia, PA 19140
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1990 - 1994
Good Samaritan Hospital of MarylandResidency, Internal Medicine, 1987 - 1990
American University of Beirut Faculty of MedicineClass of 1987
Certifications & Licensure
PA State Medical License 2011 - 2022
TX State Medical License 2004 - 2011
MD State Medical License 1989 - 2004
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2003
Clinical Trials
- Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia Start of enrollment: 2003 Jan 01
- Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders Start of enrollment: 2005 May 01
- Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases Start of enrollment: 2006 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 3500 citationsGenomic and epigenomic landscapes of adult de novo acute myeloid leukemiaTimothy J. Ley, Christopher A. Miller, Li Ding, Benjamin J. Raphael, Andrew J. Mungall
The New England Journal of Medicine. 2013-05-30 - 485 citationsDNA methylation aging clocks: challenges and recommendationsChristopher G. Bell, Robert Lowe, Peter D. Adams, Andrea A. Baccarelli, Stephan Beck
Genome Biology. 2019-11-25 - 757 citationsTargeting the cancer epigenome for therapyPeter A. Jones, Jean Pierre J. Issa, Stephen B. Baylin
Nature Reviews. Genetics. 2016-10-01
Abstracts/Posters
- Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best...Jean-Pierre Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Te...Jean-Pierre Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Na¥ve (TN) AML Unfit for Intensive Chemothe...Jean-Pierre Issa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients wit...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Engineering of CD19-Specific Chimeric Antigen Receptor T Cells with the Integrin CD103 Results in Augmented Therapeutic Efficacy Against Human Lymphoma in a Preclinica...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediat...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Coriell Institute for Medical Research Scientist Receives Grant to Find Drivers of Breast CancerDecember 5th, 2019- Predictors of Response to Guadecitabine Found in Relapsed/Refractory AML PatientsSeptember 12th, 2019
- Coriell Institute for Medical Research Now a Collaborator in Prestigious Stand up to Cancer GrantJuly 19th, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
